Out-licensing: Diagnostic & Endocrinology/Growth Disorders/Growth Hormone Replacement (other)

Latest: Watch here for details of new products and services.

About Us: Innovaro Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Pay-per-Click New!; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Innovaro Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..4 of 4 - per page
Order by

Treatment and Diagnosis of Cell Proliferative Disorders: Elucidation of Transcription Factors Regulating FGF-2 More

Identification of NTproCNP: A Novel Biomarker to Predict Abnormal Growth More

Molecular Diagnostics to Identify Individuals with Inherited Lymphedema More

Use of Methylthioadenosine Phosphorylase in the Diagnosis and Treatment of Proliferative Disorders More

Displaying 1..4 of 4 - per page
Order by

Industry sector: Diagnostic del
Therapeutic target: Endocrinology del; Growth disorders del; Growth hormone replacement (other) del

Industry sector: Antibody-based diagnostics; Biomarker-based diagnostics; CAT; Genetic diagnostics; Imaging; MRI; Nuclear medicine; Other; Self-test systems; Supplies; Test systems; Ultrasound; X-ray
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Innovaro Pharmalicensing current industry press releases.